Furthermore, AZD5991 binds directly to the MCL-1 and BAK interaction and was shown to have potent antitumor activity in vivo, as demonstrated by high tumor regression in an AML xenograft model. This evidence concerns the gene MCL1 and acute myeloid leukemia.